3 terminated, 2 unknown, 1 active not recruiting, 1 completed. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Terminated 3, Unknown 2, Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Antineoplastic Agents: new trials by email Literature Review of Antineoplastic Agents trials Research Report on Antineoplastic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects Fecal microbiota transplantation (FMT) - Fecal Microbiota Transplantation (FMT), Gastrointestinal Neoplasms | Phase 1 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 90 | 2025-09-01 | 2026-01-06 |
| A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche) Trastuzumab (proposed Trastuzumab biosimilar), Herclon - Breast Cancer, Breast Neoplasms | Phase 1 | Completed | Incepta Pharmaceuticals Ltd | 80 | 2024-01-23 | 2025-07-22 |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations BLU-451, Carboplatin, Pemetrexed - Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 103 | 2022-03-04 | 2025-02-10 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC BLU-701, osimertinib, carboplatin - Lung Neoplasm, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 20 | 2022-01-13 | 2023-06-18 |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT) - Melanoma, Unresectable Solid Tumors | Phase 1 | Active not recruiting | Yana Najjar | 50 | 2021-11-29 | 2026-08-20 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC BLU-945, osimertinib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 177 | 2021-06-29 | 2025-02-10 |
| Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) tislelizumab and BCG - Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 1 / Phase 2 | Unknown | RenJi Hospital | 6 | 2021-06-01 | 2021-06-11 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma CYNK-001 - Multiple Myeloma, Neoplasm, Plasma Cell | Phase 1 | Unknown | Celularity Incorporated | 29 | 2020-05-12 | 2023-02-16 |
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (4) · Adenocarcinoma (3) · Bronchial Neoplasms (3) · Carcinoma (3) · Carcinoma, Bronchogenic (3) · Carcinoma, Non-Small-Cell Lung (3) · Lung Diseases (3) · Lung Neoplasms (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Neoplasms, Nerve Tissue (2) · Blood Protein Disorders (1)
Bronchial Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Chemically-Induced Disorders (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1)
Carboplatin (2) · Pemetrexed (2) · osimertinib (2) · Drug Therapy (1) · Fecal Microbiota Transplantation (1) · HuMax-IL8 (1) · Nivolumab (1) · Radiosurgery (1) · Trastuzumab (1) · spartalizumab (1) · tislelizumab (1)
Blueprint Medicines Corporation (3) · Celularity Incorporated (1) · Incepta Pharmaceuticals Ltd (1) · RenJi Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Yana Najjar (1)
United States (5) · Canada (2) · China (2) · Japan (2) · South Korea (2) · Taiwan (2) · Bangladesh (1) · France (1) · Netherlands (1) · Singapore (1) · Spain (1) · United Kingdom (1)
Adrian Kilcoyne, MD (1) · Manindranath Roy (1) · Yana Najjar, MD, FACP (1)